Indivior CEO acquires 1.94M shares directly in merger
The CEO received no cash consideration other than cash in lieu of a fractional share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Indivior Pharmaceuticals, Inc. (INDV) reported a merger-related ownership exchange for Chief Executive Officer Jack A. Khattar on November 2, 2026: he acquired 1,937,986 shares of Supernus, Inc. common stock directly and 1,475,569 shares through the KBT Trust. Each outstanding Supernus Pharmaceuticals, Inc. common share was canceled and converted into the right to receive 1.5401 shares of Indivior common stock; Indivior changed its name to Supernus, Inc. Outstanding equity awards converted into corresponding awards with substantially the same terms and vesting, except performance stock unit awards became time-vesting restricted stock units.
Insider Trade Summary
Other: 8,572,810 shares
Other
23 txns
Insider
Khattar Jack A.
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Employee Stock Option (right to buy) F2, F3 | 385,025 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 462,030 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 433,153 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 308,020 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 385,025 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 431,228 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 495,912 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 510,789 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 526,113 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F4 | 616,040 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F5 | 29,754 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F6 | 61,295 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F6 | 61,295 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F7 | 45,970 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F5 | 45,970 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F5 | 45,970 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F8 | 63,133 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F6 | 63,133 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F6 | 78,917 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F5 | 47,350 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F9 | 63,133 | $0.00 | $0.00 |
| Other | Common Stock F1 | 1,937,986 | $0.00 | $0.00 |
| Other | Common Stock F1 | 1,475,569 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 3,937,295 contracts (Direct);
Restricted Stock Units — 1,221,960 contracts (Direct);
Common Stock — 1,937,986 shares (Direct);
Common Stock — 1,475,569 shares (Indirect, By the KBT Trust)
Footnotes (9)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
- F2. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards were converted into time-vesting restricted stock units.
- F3. The option vests in four equal annual installments beginning on the specified date.
- F4. These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.
- F5. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2027.
- F6. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2026.
- F7. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2030.
- F8. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2028.
- F9. These restricted stock units are settled in common stock upon vesting, which occurs on June 30, 2029.
Key Figures
Direct common stock holding after transaction: 1,937,986 shares
Common stock held through the KBT Trust after transaction: 1,475,569 shares
Merger exchange ratio: 1.5401 Indivior common shares for each Supernus Pharmaceuticals common share
+3 more
6 metrics
Direct common stock holding after transaction
1,937,986 shares
Supernus, Inc. common stock; November 2, 2026
Common stock held through the KBT Trust after transaction
1,475,569 shares
Supernus, Inc. common stock; November 2, 2026
Merger exchange ratio
1.5401 Indivior common shares for each Supernus Pharmaceuticals common share
Merger consideration
Converted employee stock option award
385,025 options; $25.59 per share exercise price
Option expiration: February 14, 2028
Converted employee stock option award
526,113 options; $32.60 per share exercise price
Option expiration: February 18, 2036
Restricted stock unit award
616,040 units
50% vest upon the merger closing
Key Terms
cash in lieu of a fractional share, equity award was assumed, exchange ratio, time-vesting restricted stock units
4 terms
equity award was assumed financial
"each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior"
exchange ratio financial
"the number of Supernus, Inc. shares equal to the number ... multiplied by the 1.5401 exchange ratio"
The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.
time-vesting restricted stock units financial
"performance stock unit awards were converted into time-vesting restricted stock units"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did INDV's merger affect Jack A. Khattar's options and RSUs?
Indivior assumed each outstanding Supernus Pharmaceuticals equity award and converted it into a corresponding Supernus, Inc. award using the 1.5401 exchange ratio; option exercise prices were divided by that ratio and rounded up to the nearest cent. Awards retained substantially the same terms, including vesting, except performance stock unit awards became time-vesting restricted stock units.
AI-generated analysis. How Rhea-AI works. Not financial advice.
